» Articles » PMID: 20070408

Expression and Regulation of Interleukin-33 in Human Monocytes

Overview
Journal Immunology
Date 2010 Jan 15
PMID 20070408
Citations 52
Authors
Affiliations
Soon will be listed here.
Abstract

Interleukin-33 (IL-33) is an IL-1 family cytokine that has a role in regulating T helper type 2 cytokines and mast cell development. Expression of IL-33 is also associated with chronic inflammatory conditions such as rheumatoid arthritis. However, there is little information regarding IL-33 in myeloid cell immune responses, which are important in immunity and inflammation. We therefore investigated the expression, intracellular location and regulation of myeloid cell IL-33 by lipopolysaccharide (LPS) from Escherichia coli and the periodontal pathogen Porphyromonas gingivalis. We detected IL-33 messenger RNA in the human promonocytic cell line THP-1, in monocytes derived from these cells and in primary human monocytes. However, IL-33 was not expressed in primary monocyte-derived dendritic cells. Stimulation of monocytes with E. coli LPS (Toll-like receptor 4 agonist) and LPS from P. gingivalis (Toll-like receptor 2 agonist) up-regulated IL-33 at both the messenger RNA and protein levels but IL-1beta and tumour necrosis factor-alpha had no effect. The IL-33 protein was mainly found in the cytoplasm of monocytes with no evidence of nuclear translocation in stimulated cells. Furthermore, no IL-33 secretion was detected after stimulation with LPS and/or ATP. These data indicate that the function, if any, of IL-33 in activated monocytes is primarily intracellular. Interestingly, immunofluorescence analysis indicated that IL-33 was sequestered in the nucleus of monocytes undergoing apoptosis but released into the extracellular milieu by LPS-stimulated cells in which necrosis had been induced by freeze-thawing. Therefore, this endorses the view that IL-33 may function as an 'alarmin' and have a role in signalling cellular damage and inflammatory disease pathogenesis through release from damaged or necrotic cells.

Citing Articles

Infectious and Commensal Bacteria in Rheumatoid Arthritis-Role in the Outset and Progression of the Disease.

Korzeniowska A, Bryl E Int J Mol Sci. 2024; 25(6).

PMID: 38542357 PMC: 10970214. DOI: 10.3390/ijms25063386.


Mast Cell Involvement in the Pathogenesis of Selected Musculoskeletal Diseases.

Gutowski L, Kanikowski S, Formanowicz D Life (Basel). 2023; 13(8).

PMID: 37629547 PMC: 10455104. DOI: 10.3390/life13081690.


Mast Cell Cytokines in Acute and Chronic Gingival Tissue Inflammation: Role of IL-33 and IL-37.

Trimarchi M, Lauritano D, Ronconi G, Caraffa A, Gallenga C, Frydas I Int J Mol Sci. 2022; 23(21).

PMID: 36362030 PMC: 9654575. DOI: 10.3390/ijms232113242.


Counteractive Effects of IL-33 and IL-37 on Inflammation in Osteoarthritis.

Rai V, Dilisio M, Samadi F, Agrawal D Int J Environ Res Public Health. 2022; 19(9).

PMID: 35565085 PMC: 9100324. DOI: 10.3390/ijerph19095690.


Plasma Interleukin-33 Cannot Predict Hip Osteonecrosis in Patients With Sickle Cell Disease: A Case-Control Study.

Agrawal A, Mohapatra E, Nanda R, Bodhey N, Sakale H, Garg A Cureus. 2022; 14(3):e23556.

PMID: 35371856 PMC: 8971072. DOI: 10.7759/cureus.23556.


References
1.
Smithgall M, Comeau M, Yoon B, Kaufman D, Armitage R, Smith D . IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells. Int Immunol. 2008; 20(8):1019-30. DOI: 10.1093/intimm/dxn060. View

2.
Foster N, Cheetham J, Taylor J, Preshaw P . VIP Inhibits Porphyromonas gingivalis LPS-induced immune responses in human monocytes. J Dent Res. 2005; 84(11):999-1004. DOI: 10.1177/154405910508401106. View

3.
Iikura M, Suto H, Kajiwara N, Oboki K, Ohno T, Okayama Y . IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab Invest. 2007; 87(10):971-8. DOI: 10.1038/labinvest.3700663. View

4.
Suzukawa M, Iikura M, Koketsu R, Nagase H, Tamura C, Komiya A . An IL-1 cytokine member, IL-33, induces human basophil activation via its ST2 receptor. J Immunol. 2008; 181(9):5981-9. DOI: 10.4049/jimmunol.181.9.5981. View

5.
Kuchler A, Pollheimer J, Balogh J, Sponheim J, Manley L, Sorensen D . Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. Am J Pathol. 2008; 173(4):1229-42. PMC: 2543089. DOI: 10.2353/ajpath.2008.080014. View